Amyris Boards The Sweet Fleet
Jim Lane Back in September 2015, we reported that Amyris inked a multi-year agreement with the US Defense Advance Research Projects Agency, the famed DARPA that gave us everything from kevlar to the Global Positioning System and the Internet the goal in this $35M agreement with the Biological Technologies Office was to create new research and development tools and technologies compressing the time to market for any new molecule by at least 10-fold in both time and cost. The story expanded this week when we heard from Amyris (AMRS) that it had completed strain engineering and...
Solazyme’s Detours on the Way to Algae Biofuel
by Debra Fiakas CFA Investors who took the time to read my last two posts on algae-based biofuel – “Algae Takes Flight” and “Emission Standards Driving Aviation Fuel Sourcing” - might have wondered why there was no mention of Solazyme, Inc. (SZYM: Nasdaq). California-based Solazyme has been pursuing algae-based oils for transportation since 2004, and managed to record its first product sales in 2011. However, that revenue was not from biofuel. On the long road to finding a scalable and efficient way to get renewable fuel from algae, Solazyme scientists found an interesting extract...
Amyris’ Sugarcane-derived Vaccine Adjuvant
by Jim Lane
COVID-19 has changed the way we do things…like drink more alcohol, wash our hands more, wear a mask, limit our gatherings and trips, but positive things have come about too. More time to connect with friends and family via online tools, a new respect for healthcare, agriculture and other essential workers, breathing cleaner air, and finding new ways to connect, entertain and innovate. Even in the bioeconomy, companies are doing the “pandemic pivot” and creating innovations to improve our future.
We’ve covered how the ethanol industry jumped in to save the day with hand sanitizer production, but today...
Bioplastics Maker Avantium’s IPO Plans
Jim Lane Here’s our 10-minute version of the filing, slightly re-organized to make sense to Earthlings instead of aliens from the Planet Prospectus. In the Netherlands, bioplastics maker Avantium is planning an initial public offering and listing of all shares on Euronext Amsterdam and Euronext Brussels. The company expects to raise up to €100 million (USD$106 million) and complete the offering by the end of the current quarter. More than half of the offering has already been secured via commitments from cornerstone investors. Avantium’s YXY technology converts plant-based sugar into chemicals and plastics, including 2,5-furandicarboxylic acid, a precursor...
Amyris In The Age Of Rapid Change
by Jim Lane
Last month, Amyris (AMRS) and Chevron (CVX) announced that Novvi and Chevron have entered into an agreement to jointly develop and bring to market novel renewable base oil technologies. Novvi is Amyris’ JV with Cosan (CZZ) to produce targeted hydrocarbon molecules from plant sugar for automotive, industrial, marine, and construction applications at unbeatable economics. Think lubricants for engines and machines.
Since launching its first commercial production in 2014, Novvi has been steadily increasing its base oil production to keep up with robust and growing demand for a variety of automotive, marine and industrial applications. Meanwhile, Chevron has one of...
BioAmber’s $150 Million IPO: The 10-Minute Version
Jim Lane A first-to-market leader in bio-succinic acid comes to the public markets with its IPO. Can BioAmber translate a lead in succinic acid’s smallish market into leadership in a vast array of high-priced renewable chemicals? Here’s our 10-minute version of the BioAmber IPO, with a translation of the risks into English. In Minnesota, BioAmber has filed an S-1 registration statement for a proposed $150 million initial public offering. The number of shares to be offered in the proposed offering and the price range for the offering have not yet been determined. The lead book-running managers for...
From Fuel To Fudge
by Debra Fiakas CFA This week the last reminder of the renewable fuels business that was once called Solazyme will be gone. The old Solazyme has abandoned the goal of producing renewable fuels using the oils from algae. Instead, under a new name TerraVia, the company is directing its algae cultivation and harvesting knowhow toward growing edible algae for food and personal care products. To make the change complete the old stock symbol ‘SYZM’ gives way this week to a new trading symbol ‘TVIA.’ No doubt there is more than just a little hope in Terra...
Amyris Aims For Huge Second Half
Jim Lane The Pharaohs of Farnesene continue to pick up momentum. In California, Amyris (AMRS) reported a net loss of $35.5M for the second quarter of 2014 on sales of $9.3M, with a 5.4 percent increase in sales over Q2 2013. Renewable product sales were $4.4M for the quarter, while “Recognized grants and collaborations revenues” reached $4.9M. In announcing results, the company highlighted: • End of quarter cash, cash equivalents and short-term investments balance of $90.2 million. • Lowest farnesene production costs to date and successful start of fragrance molecule production. • Addition of Braskem as a...
Bion: Waste To Dollars
Earlier this week Bion Environmental Technologies (BNET) received approval of a patent for its proprietary ammonia recovery process. Bion’s technology converts livestock wastes into ammonium bicarbonate. Patent protection in the U.S. paves the way for Bion to deliver an environmentally friendly chemical to the market at attractive profit margins.
Ammonium bicarbonate is used for a variety of purposes from leavening to crop additives. It is the fertilizer market that has caught Bion’s attention. The company intends to ‘close the loop’ for the agricultural sector by helping livestock producers economically dispose of waste and then delivering a fertilizer for food crops that qualifies as organic.
It is an attractive...
The Return of Advanced Biofuels
by Jim Lane
For several years now we have seen a significant number of players pivoting from biofuels towards smaller but higher-value markets in chemicals, nutrition, nutraceuticals, pharma, materials, flavorings, fragrances, cosmetics and more. We’ve reported on the proliferation of applications both in the Digest and in What’s Nuu? and indeed there’s been so much that’s Nuu, it’s been dizzying at times with all the spinning and twirling.
Capital costs and policy uncertainty have played their part, but the foot on the pedal for many has been oil prices. The scale of operations to compete with oil prices in the 2014-2017 period...
Amyris: The New Colossus Aims To Unlock Its Golden Door
Jim Lane In California, Amyris (AMRS) reported a Q2 net loss of $13.8M on revenues of $9,6M, up from $7.8M in Q2 2015. Revenues rose 27% from the corresponding period in 2015 primarily driven by the shipment of a new novel fragrance product, as well as Neossance Squalane sales. At the same time, Amyris, which has recorded $18.4M in revenues for the first half, re-affirmed guidance for the year that it would reach $90M in annual sales and positive cash flow from operations in 2017. With that, Amyris would have increased revenues by 400% in the second half,...
The “Jesus” Molecule: Paraxylene
Jim Lane The Coca-Cola Company invests in Gevo, Virent and Avantium partnerships, in the race to develop renewable plastic bottling entirely from renewables. There’s been an awful lot of press this week about progress in the search for the God particle. That’s the subatomic Higgs Boson a key, but as yet undetected, anchor in the standard model of the universe. Then there’s the Jesus molecule. As in, “Kind lord Jesus in Heaven, grant me an affordable way to make one of those.” It’s renewable PX, also known as your friend, paraxylene a key, but as...
Amyris Inks $100M+ Biofene Supply Pact
Jim Lane In California, the Eco-Emirs of Emeryville, Amyris (AMRS) executed a five year Biofene supply agreement with a global nutraceuticals company. Upping the ante from January This new, long-term agreement replaces the parties’ one-year purchase agreement, which was previously announced on January 4, 2016. More on that deal here. Under the new supply agreement, the mystery customer has agreed to a larger Biofene purchase in 2016 with an expected revenue contribution of approximately $9 million and to minimum annual purchase commitments in each of the remaining years of the agreement. In addition, under the new agreement, Amyris...
